Longeveron (LGVN) Net Cash Flow (QoQ) (2020 - 2026)
Longeveron (LGVN) Net Cash Flow (QoQ) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,222.41 Bn | 67,222.13 Bn | - |
| 2 | Nanobiotix | 1,909.44 Bn | 1,909.38 Bn | - |
| 3 | Akari Therapeutics | 989.71 Bn | 989.71 Bn | - |
| 4 | BeOne Medicines | 471.12 Bn | 466.33 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.84 Bn | 114.59 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.89 Bn | 61.14 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.74 Bn | 62.74 Bn | - |
| 8 | Argenx Se | 55.83 Bn | 50.64 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.34 Bn | 34.34 Bn | 959.66 Mn |
| 10 | Longeveron | 15.19 Bn | 15.17 Bn | 264,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 342.13% |
| Dec 31, 2025 | -320.46% |
| Sep 30, 2025 | 72.70% |
| Jun 30, 2025 | 18.59% |
| Mar 31, 2025 | -38.32% |
| Dec 31, 2024 | -134.09% |
| Sep 30, 2024 | -0.31% |
| Jun 30, 2024 | 446.79% |
| Mar 31, 2024 | -200.91% |
| Dec 31, 2023 | 482.31% |
| Sep 30, 2023 | 65.13% |
| Jun 30, 2023 | 59.47% |
| Mar 31, 2023 | -79.71% |
| Dec 31, 2022 | 53.82% |
| Sep 30, 2022 | -248.53% |
| Jun 30, 2022 | 45.89% |
| Mar 31, 2022 | -122.15% |
| Dec 31, 2021 | 324.38% |
| Sep 30, 2021 | -138.81% |
| Jun 30, 2021 | -112.57% |